The findings, set to be presented at the Society of Cardiovascular Computed Tomography Annual Scientific Meeting in San Diego, reinforce the clinical utility of the company's CaRi-Plaque and CaRi-Heart platforms. Among the highlights is work by Kenneth Chan, who demonstrates how FAI-Score analysis on both contrast and non-contrast imaging improves cardiovascular risk stratification beyond traditional metrics like plaque volume and calcium scores.
Caristo Diagnostics Showcases AI-Driven Cardiac Risk Assessment at SCCT
Three of the six finalists for the SCCT 2026 Young Investigator Award are utilizing Caristo Diagnostics' AI technology, marking a significant milestone for the firm. The research, drawn from the expansive ORFAN registry, includes the first-ever application of the FAI-Score on non-contrast cardiac CT scans.
Additional research from the ORFAN registry—a massive study tracking long-term outcomes for 80,381 cases—will be presented by Camila V. Blair and Ikboljon Sobirov. Their data emphasizes the efficacy of AI-quantified plaque analysis in predicting cardiovascular events up to a decade in advance. These sessions, alongside expert commentary from Ron Blankstein and Keith Channon, highlight a shift toward integrating AI-based inflammatory markers into standard cardiovascular care. The company, an Oxford University spin-out, continues to scale its global registry, which aims to incorporate longitudinal data from up to 250,000 patients to refine early detection and personalized preventative strategies.
Comments (0)
No comments yet. Be the first!